Video

Alasdair Coles, MD

CARE MS extension study results, discussed by Dr. Alasdair Coles at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, provide further evidence of the prolonged efficacy of alemtuzumab on both relapses and disability in multiple sclerosis.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Optical coherence tomography appears valuable for tracking MS patients over time
MDedge Neurology
VIDEO: Cognitive impairment may affect pediatric- and adult-onset MS patients similarly
MDedge Neurology
VIDEO: Genetic, environmental, clinical data converge on cause of multiple sclerosis
MDedge Neurology
Autonomic symptoms may contribute to MS-related fatigue
MDedge Neurology
VIDEO: Axial MRI better identifies extent of MS lesions in the cervical spinal cord
MDedge Neurology
VIDEO: Grants launch large-scale collaboration against progressive MS
MDedge Neurology
VIDEO: Predicting time to relapse after CIS in largest-ever study of high-risk patients
MDedge Neurology
Alemtuzumab safety and efficacy persist at 4 years in relapsing-remitting multiple sclerosis
MDedge Neurology
Factors may identify high-risk patients with clinically isolated syndrome
MDedge Neurology
Automating and Improving the EDSS—Validation of the eEDSS
MDedge Neurology